Overcoming antibiotic resistance. Interview with TAXIS CEO Greg Mario

Greg Mario, CEO of TAXIS Pharmaceuticals shares his dynamic journey from a childhood of constant relocations to spearheading the fight against antibiotic-resistant infections. Greg opens up about his immigrant grandparents' profound influence and a transformative experience with a captivating professor at Trinity College that shifted his academic focus from mechanical engineering to chemistry. This pivotal change set the foundation for his career in the pharmaceutical industry, highlighting his adaptability and dedication to human health.

Discover the fascinating evolution of Evogen, a company initially centered on bio and chemical threat detection, which pivoted to tackle central nervous system diseases under Greg's leadership. We also explore the creation of as revolutionary blood-based epilepsy diagnostic test, as well as the pressing issue of antibiotic resistance. 

Greg provides a historical perspective on antibiotics and underscores the urgent need for innovative antimicrobial treatments to combat the relentless rise of superbugs, emphasizing the resilience and adaptability required in the healthcare industry.

In the final section, we explore the relentless pursuit of funding in the biotech world through Greg's experiences with TAXIS Pharmaceuticals. Learn about the company's early days and the recent $2.7 million NIH grant for their promising efflux pump inhibitor, now on the brink of human trials. 

Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.